Merck & Co. (MRK) Q2 2024 Earnings
MRK·Reported July 30, 2024·Before market open
Merck & Co. reported Q2 2024 revenue of $16.1B, beat analyst consensus of $15.9B by $242.4M. Diluted EPS came in at $2.28, beat the $2.15 consensus by $0.13. Merck & Co. reports across 2 business segments, led by Pharmaceutical and Animal Health.
Revenue
$16.1Bbeat by $242.4M
Consensus: $15.9BDiluted EPS
$2.28beat by $0.13
Consensus: $2.15
Financial Snapshot
Trailing eight quarters through Q2 2024
Q2 2024 Earnings FAQ
Common questions about Merck & Co.'s Q2 2024 earnings report.
Merck & Co. (MRK) reported Q2 2024 earnings on July 30, 2024 before market open.
Merck & Co. reported revenue of $16.1B and diluted EPS of $2.28 for Q2 2024.
Revenue beat the consensus estimate of $15.9B by $242.4M. EPS beat the consensus estimate of $2.15 by $0.13.
You can read the 10-Q periodic report (0001628280-24-034715) directly on SEC EDGAR. The filing index links above go to sec.gov.